WALTHAM, Mass., May 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. announced today that Lewis H. Bender, Chief Executive Officer, will present at the Rodman and Renshaw 5th Annual Global Healthcare Conference on Monday May 19, 2008, at 10:00 a.m. CEST (4:00 a.m. EDT). The conference will be held at Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco.
A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.ilgenetics.com. A replay of the presentation will be available on the Interleukin Genetics website for 14 days following the presentation.
About Interleukin Genetics
Interleukin Genetics, Inc. is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit www.ilgenetics.com.
CONTACT: Media: Catherine Cloft of LaVoie Group, +1-978-745-4200 ext. 107,
or ccloft@lavoiegroup.com; or Investor Relations: Melanie Friedman, Stern
Investor Relations, +1-212-362-1200, melanie@sternir.com, both for
Interleukin Genetics, Inc.
Web site: http://www.ilgenetics.com/
